2013-04-22 16:32:02 -
Global CRO's executive leaders offer insights in managing outsourcing risk and
optimizing data in clinical development
Raleigh, N.C., Apr. 22, 2013 - INC Research, LLC, a therapeutically focused
global clinical research organization (CRO) with a Trusted Process® for
delivering reliable results, today announced CEO Jamie Macdonald and COO
Alistair Macdonald will participate in key panel discussions at this year's
Partnerships in Clinical Trials conference, April 21-24, 2013, in Orlando,
Florida. Together with Vice President, Strategic Alliances Andrew Townshend,
they will participate in four educational sessions covering a range of topics,
including managing risk in outsourced clinical trials, translating data into
meaningful insights and capturing metrics in a partnership.
"The Partnerships conference
is a perfect forum for coming together and
exchanging ideas with other industry leaders," said INC Research CEO Jamie
Macdonald. "As a leader in clinical innovation, we look forward to sharing some
of the forward-thinking strategies and tools we've been employing to drive
overall improvements in efficiency and quality in the drug development process.
Through innovation, our metrics-driven Trusted Process(®) and our extensive
therapeutic expertise, we're helping biopharms make better use of their drug
INC Research Speaker Lineup at Partnerships:
* Executive Leadership Boardroom - CEO Jamie Macdonald will participate in a
Quick-Fire Q&A session along with other invited CRO leaders as part of this
inaugural event on Monday, April 22,at 3:15 p.m. Attendees of this
invitation-only event will have an opportunity to connect and exchange ideas
on designing the clinical trial landscape of the future with C-level
executives from the top CROs.
* Jamie Macdonald also will participate in the "Managing Risk in Outsourced
Clinical Trials through Risk Assessment, Risk Sharing and Risk-based
Management Approaches," panel discussion taking place Tuesday, April 23,
from 1:30-2:15 p.m.
* COO Alistair Macdonald will participate in a panel on "Translating Data into
Meaningful Insights: Optimizing the Interface Among Key Stakeholders," also
taking place Tuesday, April 23, from 1:30-2:15 p.m.
* Andrew Townshend, Vice President of Strategic Alliances, will present
"Capturing Metrics in a Partnership: Does Fortune Favor the Brave?" on
Wednesday, April 24, from 11:30 a.m.-12:10 p.m.
As a leading CRO providing a full range of Phase I to IV clinical development
services on a worldwide scale, INC Research helps biopharms efficiently bring
new drugs to market through a proven methodology that ensures consistent
quality, reduced trial variability and complete transparency for every phase of
a development program. Using advanced data monitoring and management systems,
INC Research is able to provide a real-time status on all projects and test
sites and help identify issues before they occur, giving sponsors a high level
of visibility and predictability throughout their clinical trial programs.
For more information or to schedule a meeting at Partnerships in Clinical
Trials, visit the INC Research site or stop by Booth #219 at the conference.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to INC
Research for a complete range of customized Phase I through Phase IV programs in
all therapeutic areas and innovative pediatric and women's health trials. The
company's Trusted Process(®) methodology and therapeutic foresight lead
customers to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, NC. For more information,
please visit www.incresearch.com or follow us at @inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE